TSE:4523Pharmaceuticals
Does Real‑World Leqembi Iqlik Data And At‑Home Use Shift The Bull Case For Eisai (TSE:4523)?
Eisai and Biogen recently reported real-world data from the three-year LEADER study showing that nearly 83% of early Alzheimer’s patients on Leqembi remained stable or improved over about 17 months, and secured U.S. FDA approval for once-weekly subcutaneous Leqembi Iqlik as an at-home initiation option.
These updates suggest that Leqembi’s convenience, persistence on therapy and consistency across diverse patient groups could be increasingly important drivers of its clinical and commercial...